Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
1.840
-0.220 (-10.68%)
Dec 5, 2025, 4:00 PM EST - Market closed

Artelo Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2021 2020 - 2016
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Aug '21 2020 - 2016
Selling, General & Admin
5.424.124.235.966.294.6
Upgrade
Research & Development
7.015.995.74.325.832.84
Upgrade
Operating Expenses
12.4310.119.9310.2912.137.44
Upgrade
Operating Income
-12.43-10.11-9.93-10.29-12.13-7.44
Upgrade
Interest Expense
-0.18---0.01--
Upgrade
Interest & Investment Income
0.01--000
Upgrade
Other Non Operating Income (Expenses)
0.08-----
Upgrade
EBT Excluding Unusual Items
-12.53-10.11-9.93-10.29-12.12-7.44
Upgrade
Gain (Loss) on Sale of Investments
0.030.280.640.210.020
Upgrade
Pretax Income
-12.49-9.83-9.29-10.08-12.11-7.44
Upgrade
Net Income
-12.49-9.83-9.29-10.08-12.11-7.44
Upgrade
Net Income to Common
-12.49-9.83-9.29-10.08-12.11-7.44
Upgrade
Shares Outstanding (Basic)
110000
Upgrade
Shares Outstanding (Diluted)
110000
Upgrade
Shares Change (YoY)
23.24%8.88%4.48%27.04%79.12%403.69%
Upgrade
EPS (Basic)
-18.96-18.29-18.83-21.35-32.57-35.84
Upgrade
EPS (Diluted)
-18.96-18.29-18.83-21.35-32.58-35.84
Upgrade
Free Cash Flow
-8.18-8.35-8.21-8.01-8-6.14
Upgrade
Free Cash Flow Per Share
-12.41-15.54-16.64-16.96-21.53-29.59
Upgrade
EBITDA
------7.44
Upgrade
D&A For EBITDA
-----0
Upgrade
EBIT
-12.43-10.11-9.93-10.29-12.13-7.44
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.